You are now leaving XifaxanHE.com

Thank you for visiting XifaxanHE.com. By clicking OK, you will be taken to a website or sites where our Privacy Policy and other rules do not apply. Salix Pharmaceuticals does not possess editorial control over the content of the information on such website(s) and therefore does not warrant their accuracy and completeness. You are solely responsible for interactions with such website(s).

OKCancel

ABOUT HE

What are the symptoms of hepatic encephalopathy (HE)?

The symptoms of HE can differ from one person to another.

Also, some people with HE develop symptoms that begin slowly and get worse over time, while others develop more severe symptoms suddenly.

The range of symptoms associated with HE include:

Stage 1
  • Forgetfulness
  • Extra nervousness or excitement
  • Breath with a musty or sweet odor
Stage 2
  • Poor judgement
  • Severe personality changes
  • Worsening of handwriting
  • Loss of small hand movement
  • Tremors or shaking of hands and arms
  • Slowed or sluggish movement
Stage 3
  • Confusion
  • Not knowing where one is or where one is going
  • Inappropriate behavior
Stage 4
  • Unconsciousness
  • Coma

If you have an underlying liver disease condition and you start to develop any of these symptoms, it is important that you talk with your healthcare provider.

Round button with nurse icon that reads Enroll in H.E.L.P. for support Round button with nurse icon that reads Enroll in H.E.L.P. for support

*Eligibility criteria, terms and conditions apply.

These symptoms can have a big impact on daily life, such as:

what-are-symptoms-X

Not being able to drive a car

what-are-symptoms-X

Not being able to work

what-are-symptoms-X

Not being able to care for oneself

When HE symptoms are more severe, the condition is called “overt” HE.

Once overt HE occurs, there is a risk of more overt HE episodes, as well as hospitalization.

CLICK HERE TO LEARN ABOUT THE RISKS OF OVERT HE

INDICATIONS

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION

  • XIFAXAN is not for everyone. Do not take XIFAXAN if you have a known hypersensitivity to rifaximin, any of the rifamycin antimicrobial agents, or any of the components in XIFAXAN
  • If you take antibiotics, like XIFAXAN, there is a chance you could experience diarrhea caused by an overgrowth of bacteria (C. difficile). This can cause symptoms ranging in severity from mild diarrhea to life-threatening colitis. Contact your healthcare provider if your diarrhea does not improve or worsens.
  • Talk to your healthcare provider before taking XIFAXAN if you have severe hepatic (liver) impairment as this may cause increased effects of the medicine.
  • Tell your healthcare provider if you are taking drugs called P-glycoprotein inhibitors (such as cyclosporine) because using these drugs with XIFAXAN may lead to an increase in the amount of XIFAXAN absorbed by your body.
  • If you are pregnant, planning to become pregnant, or nursing, talk to your healthcare provider before taking XIFAXAN because XIFAXAN may cause harm to an unborn baby or nursing infant.
  • In clinical studies, the most common side effects of XIFAXAN were:
    • HE: peripheral edema (swelling, usually in the ankles or lower limbs), nausea (feeling sick to your stomach), dizziness, fatigue (feeling tired), and ascites (a buildup of fluid in the abdomen).
    • IBS-D: Nausea (feeling sick to your stomach) and an increase in liver enzymes.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For product information, adverse event reports, and product complaint reports, please contact:

Salix Product Information Call Center
Phone: 1-800-321-4576
Fax: 1-510-595-8183
Email: salixmc@dlss.com

Please click here for full Prescribing Information.

See MoreImportant Safety Information
See LessImportant Safety Information

INDICATIONS

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION

  • XIFAXAN is not for everyone. Do not take XIFAXAN if you have a known hypersensitivity to rifaximin, any of the rifamycin antimicrobial agents, or any of the components in XIFAXAN
  • If you take antibiotics, like XIFAXAN, there is a chance you could experience diarrhea caused by an overgrowth of bacteria (C. difficile). This can cause symptoms ranging in severity from mild diarrhea to life-threatening colitis. Contact your healthcare provider if your diarrhea does not improve or worsens.
  • Talk to your healthcare provider before taking XIFAXAN if you have severe hepatic (liver) impairment as this may cause increased effects of the medicine.
  • Tell your healthcare provider if you are taking drugs called P-glycoprotein inhibitors (such as cyclosporine) because using these drugs with XIFAXAN may lead to an increase in the amount of XIFAXAN absorbed by your body.
  • If you are pregnant, planning to become pregnant, or nursing, talk to your healthcare provider before taking XIFAXAN because XIFAXAN may cause harm to an unborn baby or nursing infant.
  • In clinical studies, the most common side effects of XIFAXAN were:
    • HE: peripheral edema (swelling, usually in the ankles or lower limbs), nausea (feeling sick to your stomach), dizziness, fatigue (feeling tired), and ascites (a buildup of fluid in the abdomen).
    • IBS-D: Nausea (feeling sick to your stomach) and an increase in liver enzymes.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For product information, adverse event reports, and product complaint reports, please contact:

Salix Product Information Call Center
Phone: 1-800-321-4576
Fax: 1-510-595-8183
Email: salixmc@dlss.com

Please click here for full Prescribing Information.